1177141-67-1
1177141-67-1 結(jié)構(gòu)式
基本信息
N-(2-氨基乙基)-5-氯異喹啉-8-磺酰胺二鹽酸鹽
CKI-7 Dihydrochloride
N-(2-Aminoethyl)-5-chloroisoquinoline-8-sulfonamide Dihydrochloride
常見問題列表
|
CK1 6 μM (IC 50 ) |
CK1 8.5 μM (Ki) |
Cdc7
|
SGK
|
S6K1
|
MSK1
|
CKI-7 (0.1-10 μM; 5 days; ES cells) treatment significantly increases the expression of the early neuroectodermal marker Sox1 and the number of cells positive for the neural markers nestin and βIII-tubulin, in a concentration-dependent manner.
CKI-7 (5 μM; 5 days; ES cells) treatment suppresses SFEB-induced β-catenin stabilization on day 5, indicating that CKI-7 inhibits Wnt signaling.
RT-PCR
| Cell Line: | Mouse ES cells |
| Concentration: | 0.1-10 μM |
| Incubation Time: | 5 days |
| Result: | Significantly increased the expression of the early neuroectodermal marker Sox1 and the number of cells positive for the neural markers nestin and βIII-tubulin, in a concentration-dependent manner. |
Western Blot Analysis
| Cell Line: | Mouse ES cells |
| Concentration: | 5 μM |
| Incubation Time: | 5 days |
| Result: | Suppressed SFEB-induced β-catenin stabilization on day 5. |
In vivo dose-dependent anti-tumor activity of CKI-7 is demonstrated in a SCID-Beige mouse systemic tumor model utilzing a recently isolated Philadelphia chromosome positive acute lymphoblastic leukemia cell line. Standard cell cycle synchronization studies established that exposure to CKI-7 results in cell cycle dependent caspase 3 activation and apoptotic cell death.